Skyonic raises $128M, plans its first commercial CO2-to-baking soda plant this summer

A Texan startup that turns carbon emissions into baking soda (among other things) has raised a huge new round and plans to break ground on its first commercial scale plant this summer. And we thought all those capital intensive cleantech startups were long gone.Austin-based Skyonic announced on Tuesday that it's raised a $128 million Series C round from big name players in the oil and gas industries, which will help fund its inaugural commercial ...

http://gigaom.com/2013/06/25/skyonic-raises-128m-plans-to-start-buildi

Alstom at COP17: Highlighting the role of business in the climate change challenge

Alstom highlights the role of business in addressing the climate change challenge at the 17th Conference of the Parties (COP17) to the United Nations Framework Convention on Climate Change (UNFCCC), held in Durban from November 28 to December 9, 2011. 

Codexis Aims to Bridge Biotech and Carbon Capture

Codexis, a Redwood City, Calif.-based startup with oil giants Shell and Chevron among its backers, is in the business of so-called evolved biocatalysts: It takes a natural microbe or enzyme and tweaks the DNA sequences to create new variants, then searches for the variants best suited to development of new, potentially cheaper drugs (Pfizer used Codexis enzymes to produce Lipitor) and non-ethanol biofuels. This summer, the 7-year-old startup said it was looking for ways to apply this expertise to the emerging market for carbon capture technologies. Now Codexis has found a partner in that effort. Canadian carbon capture company CO2 Solution said late Tuesday afternoon that it’s scored a $2 million investment from Codexis, and that the two companies will work together on enzymatic carbon capture technology. According to the release, Codexis now owns a more than 16 percent stake in the firm. They plan to work on “economic validation” of enzymatic carbon capture technology.

Codexis Aims to Bridge Biotech and Carbon Capture

Codexis, a Redwood City, Calif.-based startup with oil giants Shell and Chevron among its backers, is in the business of so-called evolved biocatalysts: It takes a natural microbe or enzyme and tweaks the DNA sequences to create new variants, then searches for the variants best suited to development of new, potentially cheaper drugs (Pfizer used Codexis enzymes to produce Lipitor) and non-ethanol biofuels. This summer, the 7-year-old startup said it was looking for ways to apply this expertise to the emerging market for carbon capture technologies. Now Codexis has found a partner in that effort. Canadian carbon capture company CO2 Solution said late Tuesday afternoon that it’s scored a $2 million investment from Codexis, and that the two companies will work together on enzymatic carbon capture technology. According to the release, Codexis now owns a more than 16 percent stake in the firm. They plan to work on “economic validation” of enzymatic carbon capture technology.